Advertisement

Effects of Valsartan Versus Amlodipine in Diabetic Hypertensive Patients With or Without Previous Cardiovascular Disease

Published:September 16, 2013DOI:https://doi.org/10.1016/j.amjcard.2013.07.043
      Recently, we reported that angiotensin II receptor blocker (ARB), valsartan, and calcium channel blocker (CCB), amlodipine, had similar effects on the prevention of cardiovascular disease (CVD) events in diabetic hypertensive patients. We assessed the difference of cardiovascular protective effects between ARB and CCB in patients with and without previous CVD, respectively. A total of 1,150 Japanese diabetic hypertensive patients were randomized to either valsartan or amlodipine treatment arms, which were additionally divided into 2 groups according to the presence of previous CVD at baseline (without CVD, n = 818; with CVD, n = 332). The primary composite outcomes were sudden cardiac death, acute myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure. The incidence of primary end point events in patients with previous CVD was 3.5-times greater than that in patients without previous CVD (64.1 vs 17.9/1,000 person-years). The ARB- and the CCB-based treatment arms showed similar incidence of composite CVD events in both patients without previous CVD (hazard ratio [HR] 1.35, 95% confidence interval [CI] 0.76 to 2.40) and those with previous CVD (HR 0.79, 95% CI 0.48 to 1.31). The ARB-treatment arm showed less incidence of stroke compared with the CCB-based treatment arm in patients with previous CVD (HR 0.24, 95% CI 0.05 to 1.11, p = 0.068), whereas the 2 treatment arms showed similar incidence of stroke in patients without previous CVD (HR 1.52, 95% CI 0.59 to 3.91). In conclusion, the ARB- and the CCB-based treatments exerted similar protective effects of CVD events regardless of the presence of previous CVD. For stroke events, the ARB may have more protective effects than the CCB in diabetic hypertensive patients with previous CVD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Matsushita K.
        • Muramatsu T.
        • Kondo T.
        • Maeda K.
        • Shintani S.
        • Murohara T.
        Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance.
        J Cardiol. 2010; 56: 111-117
        • Muramatsu T.
        • Matsushita K.
        • Yamashita K.
        • Kondo T.
        • Maeda K.
        • Shintani S.
        • Ichimiya S.
        • Ohno M.
        • Sone T.
        • Ikeda N.
        • Watarai M.
        • Murohara T.
        Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study.
        Hypertension. 2012; 59: 580-586
        • American Diabetes Association
        Standards of medical care in diabetes.
        Diabetes Care. 2004; 27: S15-35
      1. Japan Diabetes Society Treatment Guide for Diabetes 2007 (English Version). Nankodo, Tokyo, Japan2007
        • Julius S.
        • Kjeldsen S.E.
        • Weber M.
        • Brunner H.R.
        • Ekman S.
        • Hansson L.
        • Hua T.
        • Laragh J.
        • McInnes G.T.
        • Mitchell L.
        • Plat F.
        • Schork A.
        • Smith B.
        • Zanchetti A.
        Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
        Lancet. 2004; 363: 2022-2031
        • Julius S.
        • Weber M.A.
        • Kjeldsen S.E.
        • McInnes G.T.
        • Zanchetti A.
        • Brunner H.R.
        • Laragh J.
        • Schork M.A.
        • Hua T.A.
        • Amerena J.
        • Balazovjech I.
        • Cassel G.
        • Herczeg B.
        • Koylan N.
        • Magometschnigg D.
        • Majahalme S.
        • Martinez F.
        • Oigman W.
        • Seabra Gomes R.
        • Zhu J.R.
        The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
        Hypertension. 2006; 48: 385-391
        • Zanchetti A.
        • Julius S.
        • Kjeldsen S.
        • McInnes G.T.
        • Hua T.
        • Weber M.
        • Laragh J.H.
        • Plat F.
        • Battegay E.
        • Calvo-Vargas C.
        • Cieslinski A.
        • Degaute J.P.
        • Holwerda N.J.
        • Kobalava J.
        • Pedersen O.L.
        • Rudyatmoko F.P.
        • Siamopoulos K.C.
        • Storset O.
        Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial.
        J Hypertens. 2006; 24: 2163-2168
        • Narumi H.
        • Takano H.
        • Shindo S.
        • Fujita M.
        • Mizuma H.
        • Kuwabara Y.
        • Komuro I.
        Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial.
        Hypertens Res. 2011; 34: 62-69
        • Ueshima K.
        • Oba K.
        • Yasuno S.
        • Fujimoto A.
        • Tanaka S.
        • Ogihara T.
        • Saruta T.
        • Nakao K.
        Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients.—Primary and secondary prevention of ischemic heart disease in a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
        Circ J. 2011; 75: 2411-2416
        • Kubo M.
        • Kiyohara Y.
        • Kato I.
        • Tanizaki Y.
        • Arima H.
        • Tanaka K.
        • Nakamura H.
        • Okubo K.
        • Iida M.
        Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study.
        Stroke. 2003; 34: 2349-2354
        • Ueshima H.
        Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke.
        J Atheroscler Thromb. 2007; 14: 278-286
        • Schrader J.
        • Luders S.
        • Kulschewski A.
        • Hammersen F.
        • Plate K.
        • Berger J.
        • Zidek W.
        • Dominiak P.
        • Diener H.C.
        Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
        Stroke. 2005; 36: 1218-1226
        • Weber M.A.
        • Julius S.
        • Kjeldsen S.E.
        • Brunner H.R.
        • Ekman S.
        • Hansson L.
        • Hua T.
        • Laragh J.H.
        • McInnes G.T.
        • Mitchell L.
        • Plat F.
        • Schork M.A.
        • Smith B.
        • Zanchetti A.
        Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.
        Lancet. 2004; 363: 2049-2051
        • Asanuma H.
        • Minamino T.
        • Sanada S.
        • Ogita H.
        • Kim J.
        • Fujita M.
        • Hirata A.
        • Tsukamoto O.
        • Ogai A.
        • Node K.
        • Hori M.
        • Tomoike H.
        • Kitakaze M.
        A calcium channel blocker amlodipine increases coronary blood flow via both adenosine- and NO-dependent mechanisms in ischemic hearts.
        J Mol Cell Cardiol. 2005; 39: 605-614
        • Berl T.
        • Hunsicker L.G.
        • Lewis J.B.
        • Pfeffer M.A.
        • Porush J.G.
        • Rouleau J.L.
        • Drury P.L.
        • Esmatjes E.
        • Hricik D.
        • Parikh C.R.
        • Raz I.
        • Vanhille P.
        • Wiegmann T.B.
        • Wolfe B.M.
        • Locatelli F.
        • Goldhaber S.Z.
        • Lewis E.J.
        Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
        Ann Intern Med. 2003; 138: 542-549
        • Turnbull F.
        • Neal B.
        • Algert C.
        • Chalmers J.
        • Chapman N.
        • Cutler J.
        • Woodward M.
        • MacMahon S.
        Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.
        Arch Intern Med. 2005; 165: 1410-1419
        • Chiu K.C.
        • Cohan P.
        • Lee N.P.
        • Chuang L.M.
        Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function.
        Diabetes Care. 2000; 23: 1353-1358
        • Raji A.
        • Seely E.W.
        • Arky R.A.
        • Simonson D.C.
        Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians.
        J Clin Endocrinol Metab. 2001; 86: 5366-5371
        • Fukushima M.
        • Suzuki H.
        • Seino Y.
        Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes.
        Diabetes Res Clin Pract. 2004; 66: S37-S43
        • Ferrannini E.
        • Buzzigoli G.
        • Bonadonna R.
        • Giorico M.A.
        • Oleggini M.
        • Graziadei L.
        • Pedrinelli R.
        • Brandi L.
        • Bevilacqua S.
        Insulin resistance in essential hypertension.
        N Engl J Med. 1987; 317: 350-357
        • Grundy S.M.
        • Cleeman J.I.
        • Daniels S.R.
        • Donato K.A.
        • Eckel R.H.
        • Franklin B.A.
        • Gordon D.J.
        • Krauss R.M.
        • Savage P.J.
        • Smith Jr., S.C.
        • Spertus J.A.
        • Costa F.
        Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.
        Circulation. 2005; 112: 2735-2752